Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis.
We report a rare case of advanced lung cancer with epidermal growth factor receptor and anaplastic lymphoma kinase co-alterations and brain metastasis, in which icotinib treatment was effective for both the primary lung tumor and the brain metastasis. The patient achieved important clinical remission with a progression-free survival for two years. Our treatment strategy appears to be a promising therapeutic approach for this subgroup of patients.
Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine.
Chenyang
C
Ye
Department of Surgical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University.
Ji
J
Wang
Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine.
Shu
S
Zheng
Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Ying
Y
Chai
ALK; EGFR; brain metastasis; icotinib; lung cancer